Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jun 3;6(6):CD012352.
doi: 10.1002/14651858.CD012352.pub2.

Screening for reducing morbidity and mortality in malignant melanoma

Minna Johansson  1 , John Brodersen, Peter C Gøtzsche, Karsten Juhl Jørgensen
Affiliations
Meta-Analysis

Screening for reducing morbidity and mortality in malignant melanoma

Minna Johansson et al. Cochrane Database Syst Rev. .

Abstract

Background: Screening for malignant melanoma has the potential to reduce morbidity and mortality from the disease through earlier detection, as prognosis is closely associated with the thickness of the lesion at the time of diagnosis. However, there are also potential harms from screening people without skin lesion concerns, such as overdiagnosis of lesions that would never have caused symptoms if they had remained undetected. Overdiagnosis results in harm through unnecessary treatment and the psychosocial consequences of being labelled with a cancer diagnosis. For any type of screening, the benefits must outweigh the harms. Screening for malignant melanoma is currently practised in many countries, and the incidence of the disease is rising sharply, while mortality remains largely unchanged.

Objectives: To assess the effects on morbidity and mortality of screening for malignant melanoma in the general population.

Search methods: We searched the following databases up to May 2018: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registries, checked the reference lists of included and other relevant studies for further references to randomised controlled trials (RCTs), used citation tracking (Web of Science) for key articles, and asked trialists about additional studies and study reports.

Selection criteria: RCTs, including cluster-randomised trials, of screening for malignant melanoma compared with no screening, regardless of screening modality or setting, in any type of population and in any age group where people were not suspected of having malignant melanoma. We excluded studies in people with a genetic disposition for malignant melanoma (e.g. familial atypical mole and melanoma syndrome) and studies performed exclusively in people with previous melanomas.

Data collection and analysis: We used standard methodological procedures expected by Cochrane. The primary outcomes of this review were total mortality, overdiagnosis of malignant melanoma, and quality of life/psychosocial consequences.

Main results: We included two studies with 64,391 participants. The first study was a randomised trial of an intervention developed to increase the rate of performance of thorough skin self-examination. The intervention group received instructional materials, including cues and aids, a 14-minute instruction video, and a brief counselling session, and at three weeks a brief follow-up telephone call from a health educator, aimed at increasing performance of thorough skin self-examination. The control group received a diet intervention with similar follow-up. The trial included 1356 people, who were recruited from 11 primary care practices in the US between 2000 and 2001. Participant mean age was 53.2 years and 41.7% were men. This study did not report on any of our primary outcomes or the following secondary outcomes: mortality specific to malignant melanoma, false-positive rates (skin biopsies/excisions with benign outcome), or false-negative rates (malignant melanomas diagnosed between screening rounds and up to one year after the last round). All participants were asked to complete follow-up telephone interviews at 2, 6, and 12 months after randomisation.The second study was a pilot study for a cluster-RCT of population-based screening for malignant melanoma in Australia. This pilot trial included 63,035 adults aged over 30 years. The three-year programme involved community education, an education and support component for medical practitioners, and the provision of free skin screening services. The mean age of people attending the skin screening clinics (which were held by primary care physicians in workplaces, community venues, and local hospitals, and included day and evening sessions) was 46.5 years, and 51.5% were men. The study included whole communities, targeting participants over 30 years of age, but information on age and gender of the whole study population was not reported. Study duration was three years (1998 to 2001), and outcomes were measured at the screening clinics during these three years. There was no further follow-up for any outcomes. The control group received no programme. The ensuing, planned cluster randomised trial in 560,000 adults was never carried out due to lack of funding. At the time of this review, there are no published or unpublished data on our prespecified outcomes available, and no results for mortality outcomes from the pilot study are to be expected.The risk of bias in these studies was high for performance bias (blinding study personnel and participants) and high or unclear for detection bias (blinding of outcome assessment). Risk of bias in the other domains was either unclear or low. We were unable to assess the certainty of the evidence for our primary outcomes as planned due to lack of data.

Authors' conclusions: Adult general population screening for malignant melanoma is not supported or refuted by current evidence from RCTs. It therefore does not fulfil accepted criteria for implementation of population screening programmes. This review did not investigate the effects of screening people with a history of malignant melanoma or in people with a genetic disposition for malignant melanoma (e.g. familial atypical mole and melanoma syndrome). To determine the benefits and harms of screening for malignant melanoma, a rigorously conducted randomised trial is needed, which assesses overall mortality, overdiagnosis, psychosocial consequences, and resource use.

PubMed Disclaimer

Conflict of interest statement

MJ: none known. JB: none known. PCG: none known. KJJ: none known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Aitken 2002 {published data only (unpublished sought but not used)}
    1. Aitken JF, Elwood JM, Lowe JB, Firman DW, Balanda KP, Ring IT. A randomised trial of population screening for melanoma. Journal of Medical Screening 2002;9(1):33‐7. [CENTRAL: CN‐00397415] - PubMed
    1. Aitken JF, Janda M, Elwood M, Youl PH, Ring IT, Lowe JB. Clinical outcomes from skin screening clinics within a community‐based melanoma screening program. Journal of the American Academy of Dermatology 2006;54(1):105‐14. [CENTRAL: CN‐00561884] - PubMed
    1. Aitken JF, Youl PH, Janda M, Lowe JB, Ring IT, Elwood M. Increase in skin cancer screening during a community‐based randomized intervention trial. International Journal of Cancer 2006;118(4):1010‐6. [CENTRAL: CN‐00622539] - PubMed
    1. Lowe JB, Ball J, Lynch BM, Baldwin L, Janda M, Stanton WR, et al. Acceptability and feasibility of a community‐based screening programme for melanoma in Australia. Health Promotion International 2004;19(4):437‐44. [CENTRAL: CN‐00501882; DOI: 10.1093/heapro/dah405; PUBMED: 15520039] - DOI - PubMed
    1. Youl PH, Janda M, Elwood M, Lowe JB, Ring IT, Aitken JF. Who attends skin cancer clinics within a randomized melanoma screening program?. Cancer Detection and Prevention 2006;30(1):44‐51. [CENTRAL: CN‐00562466; PUBMED: 16457967] - PubMed
Weinstock 2007 {published data only}
    1. Weinstock M, Risica P, Martin R, Rakowski W, Dubé C, Berwick M, et al. Melanoma early detection with thorough skin self‐examination: the "Check It Out" randomized trial. American Journal of Preventive Medicine 2007;32(6):517‐24. [CENTRAL: CN‐00589286] - PMC - PubMed

References to studies excluded from this review

Breitbart 2012 {published data only}
    1. Breitbart EW, Waldmann A, Nolte S, Capellaro M, Greinert R, Volkmer B, et al. Systematic skin cancer screening in Northern Germany. Journal of American Academy of Dermatology 2012;66(2):201‐11. [PUBMED: 22074699] - PubMed
Emmons 2011 {published data only}
    1. Emmons KM, Geller AC, Puleo E, Savadatti SS, Hu SW, Gorham S, et al. Skin cancer education and early detection at the beach: a randomized trial of dermatologist examination and biometric feedback. Journal of the American Academy of Dermatology 2011;64:282‐9. [CENTRAL: CN‐00770617] - PMC - PubMed
Geller 2006 {published data only}
    1. Geller AC, Emmons KM, Brooks DR, Powers C, Zhang Z, Koh HK, et al. A randomized trial to improve early detection and prevention practices among siblings of melanoma patients. Cancer 2006;107(4):806‐14. [CENTRAL: CN‐00566452] - PubMed
Girgis 1994 {published data only}
    1. Girgis A, Sanson‐Fisher RW, Watson A. A workplace intervention for increasing outdoor workers' use of solar protection. American Journal of Public Health 1994;84(1):77‐81. [CENTRAL: CN‐00098178] - PMC - PubMed
Greaney 2012 {published data only}
    1. Greaney ML, Puleo E, Geller AC, Hu SW, Werchniak AE, DeCristofaro S, et al. Patient follow‐up after participating in a beach‐based skin cancer screening program. International Journal of Environmental Research and Public Health 2012;9(5):1836‐45. [CENTRAL: CN‐00859719] - PMC - PubMed
Hiramoto 1986 {published data only}
    1. Hiramoto T, Inoue S, Kanazawa K, Yamane Y, Kitajima Y, Yaoita H. A trial of mass screening for skin cancer. Nihon Hifuka Gakkai Zasshi [Japanese Journal of Dermatology] 1986;96(5):503‐8. [PUBMED: 3735724] - PubMed
Katalinic 2012 {published data only}
    1. Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R, et al. Does skin cancer screening save lives? An observational study comparing trends in melanoma mortality in regions with and without screening. Cancer 2012;118(21):5395‐402. [PUBMED: 22517033] - PubMed
Oivanen 2008 {published data only}
    1. Oivanen T, Kojo K, Pylkkanen L, Holli K, Auvinen A. Early detection of skin cancer as public health policy: comparison of campaign and routine activity. Preventive Medicine 2008;46(2):160‐5. [PUBMED: 17919714] - PubMed
Rat 2012 {published data only}
    1. Rat C, Quereux G, Riviere C, Clouet S, Senand R, Dreno B, et al. Impact of a targeted screening on melanoma prevention behaviour. A randomised controlled trial. Journal of Investigative Dermatology 2012;132:S71. [CENTRAL: CN‐01008101]
Rat 2014 {published data only}
    1. Rat C, Quereux G, Riviere C, Clouet S, Senand R, Volteau C, et al. Targeted melanoma prevention intervention: a cluster randomized controlled trial. Annals of Family Medicine 2014;12(1):21‐8. [CENTRAL: CN‐01014253] - PMC - PubMed
Robinson 2014 {published data only}
    1. Robinson JK, Gaber R, Hultgren B, Eilers S, Blatt H, Stapleton J, et al. Skin self‐examination education for early detection of melanoma: a randomized controlled trial of Internet, workbook, and in‐person interventions. Journal of Medical Internet Research 2014;16(1):e7. [CENTRAL: CN‐01002337] - PMC - PubMed
Robinson 2016b {published data only}
    1. Robinson JK, Wayne JD, Martini MC, Hultgren BA, Mallett KA, Turrisi R. Early detection of new melanomas by patients with melanoma and their partners using a structured skin self‐examination skills training intervention: a randomized clinical trial. JAMA Dermatology 2016;152(9):979‐85. [CENTRAL: CN‐01286352] - PMC - PubMed
Snow 1989 {published data only}
    1. Snow SG, Calder EA, Taylor LS, Lane TJ, Manu P, Federici CM. Screening for cancer and coronary risk factors through a nurse practitioner‐staffed preventive health clinic. Preventive Medicine 1989;18(6):817‐23. [PUBMED: 2516628] - PubMed
Törnberg 1996 {published data only}
    1. Törnberg S, Månsson‐Brahme E, Lindén D, Ringborg U, Krakau I, Kärnell R, et al. Screening for cutaneous malignant melanoma: a feasibility study. Journal of Medical Screening 1996;3(4):211‐5. [CENTRAL: CN‐00266786] - PubMed
Walton 2014 {published data only}
    1. Walton AE, Janda M, Youl PH, Baade P, Aitken JF, Whiteman DC, et al. Uptake of skin self‐examination and clinical examination behavior by outdoor workers. Archives of Environmental and Occupational Health 2014;69(4):214‐22. [CENTRAL: CN‐00983286] - PubMed
Youl 2005 {published data only}
    1. Youl PH, Janda M, Lowe JB, Aitken JF. Does the type of promotional material influence men's attendance at skin screening clinics?. Health Promotion Journal of Australia 2005;16(3):229‐32. [PUBMED: 16375040] - PubMed

Additional references

ACNMGRWP 2008
    1. Australian Cancer Network Melanoma Guidelines Revision Working Party 2008. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/Cli... (accessed 14 June 2016).
Aitken 2010
    1. Aitken JF, Elwood M, Baade PD, Youl P, English D. Clinical whole‐body skin examination reduces the incidence of thick melanomas. International Journal of Cancer 2010;126(2):450‐8. [PUBMED: 19609948] - PubMed
Aitken 2017 [pers comm]
    1. Aitken J. Email enquiry. E‐mail to: M Johansson 2 March 2017.
American Academy of Dermatology 2017
    1. American Academy of Dermatology. 30 years of free skin cancer screening. www.aad.org/public/spot‐skin‐cancer/programs/screenings/30‐years‐of‐skin... (accessed 5 January 2017).
American Cancer Society 2017
    1. American Cancer Society. Skin cancer prevention and early detection. www.cancer.org/cancer/cancercauses/sunanduvexposure/skincancerprevention... (accessed 5 January 2017).
Autier 2015
    1. Autier P, Koechlin A, Boniol M. The forthcoming inexorable decline of cutaneous melanoma mortality in light‐skinned populations. European Journal of Cancer 2015;51(7):869‐78. [PUBMED: 25771950] - PubMed
Balanda 1994
    1. Balanda KP, Lowe JB, Stanton WR, Gillespie AM. Enhancing the early detection of melanoma within current guidelines. Australian Journal of Public Health 1994;18(4):420‐3. [PUBMED: 7718657] - PubMed
Biesheuvel 2007
    1. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncology 2007;8(12):1129‐38. [PUBMED: 18054882] - PubMed
Black 2002
    1. Black WC, Haggstrom DA, Welch HG. All‐cause mortality in randomized trials of cancer screening. Journal of the National Cancer Institute 2002;94(3):167‐73. [PUBMED: 11830606] - PubMed
Boniol 2015
    1. Boniol M, Autier P, Gandini S. Melanoma mortality following skin cancer screening in Germany. BMJ Open 2015;5(9):e008158. [PUBMED: 26373399] - PMC - PubMed
Borland 1995
    1. Borland R, Meehan JW. Skin examination for signs of cancer. Australian Journal of Public Health 1995;19(1):85‐8. [PUBMED: 7734602] - PubMed
Breitbart 2014
    1. Breitbart EW, Choudhury K, Anders MP, Volkmer B, Greinert R, Katalinic A, et al. Benefits and risks of skin cancer screening. Oncology Research Treatment 2014;37(3):38‐47. [PUBMED: 25195831] - PubMed
Breslow 1970
    1. Breslow A. Thickness, cross‐sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Annals of Surgery 1970;172(5):902‐8. [PUBMED: 5477666] - PMC - PubMed
Brochez 2001
    1. Brochez L, Verhaeghe E, Bleyen L, Naeyaert JM. Diagnostic ability of general practitioners and dermatologists in discriminating pigmented skin lesions. Journal of the American Academy of Dermatology 2001;44(6):979‐86. [PUBMED: 11369910 ] - PubMed
Brodersen 2013
    1. Brodersen J, Siersma VD. Long‐term psychosocial consequences of false‐positive screening mammography. Annals of Family Medicine 2013;11(2):106‐15. [PUBMED: 23508596] - PMC - PubMed
Brok 2008
    1. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology 2008;61(8):763‐9. [PUBMED: 18411040] - PubMed
Cancer Australia 2016
    1. Cancer Australia. Melanoma of the skin statistics 2016. melanoma.canceraustralia.gov.au/statistics (accessed 8 February 2017).
Coups 2010
    1. Coups EJ, Geller AC, Weinstock MA, Heckman CJ, Manne SL. Prevalence and correlates of skin cancer screening among middle‐aged and older white adults in the United States. American Journal of Medicine 2010;123(5):439‐45. [PUBMED: 20399321] - PMC - PubMed
Covidence [Computer program]
    1. Veritas Health Innovation. Covidence. Version accessed prior to 30 May 2018. Melbourne, Australia: Veritas Health Innovation.
CTFPHC 2013
    1. Canadian Task Force on Preventive Health Care 2013. Melanoma critical appraisal report. canadiantaskforce.ca/appraised‐guidelines/2013‐melanoma/ (accessed 14 June 2016).
Curiel‐Lewandrowski 2012
    1. Curiel‐Lewandrowski C, Chen SC, Swetter SM. Screening and prevention measures for melanoma: is there a survival advantage?. Current Oncology Reports 2012;14(5):458‐67. [EMBASE: 2012713710] - PMC - PubMed
Dinnes 2015
    1. Dinnes J, Matin RN, Moreau JF, Patel L, Chan SA, Chuchu N, et al. Tests to assist in the diagnosis of cutaneous melanoma in adults: a generic protocol. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD011902] - DOI
EADO 2016
    1. European Association of Dermato Oncology. Euro melanoma. www.euromelanoma.org (accessed 14 June 2016).
Federman 1997
    1. Federman DG, Concato J, Caralis PV, Hunkele GE, Kirsner RS. Screening for skin cancer in primary care settings. Archives of Dermatological Research 1997;133(11):1423‐5. [PUBMED: 9371027] - PubMed
Federman 2006
    1. Federman DG, Kravetz JD, Haskell SG, Ma F, Kirsner RS. Full‐body skin examinations and the female veteran: prevalence and perspective. Archives of Dermatological Research 2006;142(3):312‐6. [PUBMED: 16549706] - PubMed
Ford 2004
    1. Ford JS, Ostroff JS, Hay JL, Buckley TR, Stein TR, Berwick M, et al. Participation in annual skin cancer screening among women seeking routine mammography. Preventive Medicine 2004;38(6):704‐12. [PUBMED: 15193890] - PubMed
Gandini 2005
    1. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta‐analysis of risk factors for cutaneous melanoma: II sun exposure. European Journal of Cancer 2005;41(1):45‐60. [PUBMED: 15617990] - PubMed
Garbe 2009
    1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clinics in Dermatology 2009;27(1):3‐9. [PUBMED: 19095149] - PubMed
Geller 2015
    1. Geller AC, Swetter SM, Weinstock MA. Focus on early detection to reduce melanoma deaths. Journal of Investigative Dermatology 2015;135(4):947‐9. [PUBMED: 25785949] - PubMed
Girgis 1991
    1. Girgis A, Campbell EM, Redman S, Sanson‐Fisher RW. Screening for melanoma: a community survey of prevalence and predictors. Medical Journal of Australia 1991;154(5):338‐43. [PUBMED: 2017062] - PubMed
Goldenberg 2016
    1. Goldenberg AJ, Comeau AM, Grosse SD, Tansley S, Prosser LA, Ojodu J, et al. Evaluating harms in the assessment of net benefit: a framework for newborn screening condition review. Maternal and Child Health Journal 2016;20(3):693‐700. [PUBMED: 26833040] - PMC - PubMed
Green 2011
    1. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow‐up. Journal of Clinical Oncology 2011;29(3):257‐63. [PUBMED: 21135266] - PubMed
Gruber 2006
    1. Gruber SB, Armstrong BK. Cutaneous and ocular melanoma. In: Schottenfeld D, Fraumeni J editor(s). Cancer Epidemiology and Prevention. New York (NY): Oxford University Press, 2006.
Gøtzsche 2013
    1. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD001877.pub5] - DOI - PMC - PubMed
Harris 2014
    1. Harris RP, Sheridan SL, Lewis CL, Barclay C, Vu MB, Kistler CE, et al. The harms of screening: a proposed taxonomy and application to lung cancer screening. JAMA Internal Medicine 2014;174(2):281‐6. [PUBMED: 24322781] - PubMed
Heywood 1994
    1. Heywood A, Sanson‐Fisher R, Ring I, Mudge P. Risk prevalence and screening for cancer by general practitioners. Preventive Medicine 1994;23(2):152‐9. [PUBMED: 8047520] - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hudis 2015
    1. Hudis CA. Biology before anatomy in early breast cancer – precisely the point. New England Journal of Medicine 2015;373(21):2079‐80. [PUBMED: 26412350] - PubMed
Janda 2004
    1. Janda M, Elwood M, Ring IT, Firman DW, Lowe JB, Youl PH, et al. Prevalence of skin screening by general practitioners in regional Queensland. Medical Journal of Australia 2004;180(1):10‐5. [PUBMED: 14709121] - PubMed
Johnson‐Obaseki 2015
    1. Johnson‐Obaseki SE, Labajian V, Corsten MJ, McDonald JT. Incidence of cutaneous malignant melanoma by socioeconomic status in Canada: 1992–2006. Journal of Otolaryngology 2015;44(1):53‐9. [DOI: 10.1186/s40463-015-0107-1; EMBASE: 20160690459] - DOI - PMC - PubMed
Katalinic 2015
    1. Katalinic A, Eisemann N, Waldmann A. Skin cancer screening in Germany. Documenting melanoma incidence and mortality from 2008 to 2013. Deutsches Arzteblatt International 2015;112(38):629‐34. [DOI: 10.3238/arztebl.2015.0629; PUBMED: 26429634] - DOI - PMC - PubMed
Keen 2015
    1. Keen JD, Jørgensen KJ. Four principles to consider before advising women on screening mammography. Journal of Women's Health 2015;24(11):867‐74. [PUBMED: 26496048] - PMC - PubMed
Kirkham 2010
    1. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [PUBMED: 20156912] - PubMed
Krogsbøll 2012
    1. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD009009.pub2] - DOI - PubMed
Lakhani 2014
    1. Lakhani NA, Saraiya M, Thompson TD, King SC, Guy GP Jr. Total body skin examination for skin cancer screening among U.S. adults from 2000 to 2010. Preventive Medicine 2014;61:75‐80. [DOI: 10.1016/j.ypmed.2014.01.003; PUBMED: 24418263] - DOI - PMC - PubMed
Langbecker 2014
    1. Langbecker D, Diaz A, Chan RJ, Marquart L, Hevey D, Hamilton J. Educational programmes for primary prevention of skin cancer. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD011061] - DOI
Lazovich 2016
    1. Lazovich D, Isaksson Vogel R, Weinstock MA, Nelson HH, Ahmed RL, Berwick M. Association between indoor tanning and melanoma in younger men and women. JAMA Dermatology 2016;152(3):268‐75. [PUBMED: 26818409] - PMC - PubMed
Marks 2000
    1. Marks R. Epidemiology of melanoma. Clinical and Experimental Dermatology 2000;25(6):459‐63. [PUBMED: 11044179] - PubMed
McCleskey 2015
    1. McCleskey PE. Commentary: to improve melanoma detection, help teach our colleagues. Journal of the American Academy of Dermatology 2015;73(6):966‐7. [PUBMED: 26478213] - PubMed
McFarland 2015
    1. McFarland SL, Schram SE. Physician skin examinations for melanoma screening. Cutis 2015;96(3):175‐82. [PUBMED: 26562268] - PubMed
Moher 2010
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche P, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [PUBMED: 20332511] - PMC - PubMed
National Cancer Institute 2016
    1. National Cancer Institute, Bethesda, MD. SEER Cancer Statistics Review, 1975‐2013. seer.cancer.gov/csr/1975_2013/results_merged/topic_lifetime_risk.pdf (accessed 8 February 2017).
Norgaard 2011
    1. Norgaard C, Glud M, Gniadecki R. Are all melanomas dangerous?. Acta Dermato‐venereologica 2011;91(5):499‐503. [PUBMED: 21874217] - PubMed
Prasad 2016
    1. Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to "save lives" – and what we can do about it. BMJ 2016;352:h6080. [PUBMED: 26740343] - PubMed
Raffle 2007
    1. Raffle A, Gray M. Screening – Evidence and Practice. New York (NY): Oxford University Press, 2007.
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Robinson 2016a
    1. Robinson JK, Halpern AC. Cost‐effective melanoma screening. JAMA Dermatology 2016;152(1):19‐21. [PUBMED: 26465644] - PMC - PubMed
Sackett 2002
    1. Sackett D. The arrogance of preventive medicine. CMAJ : Canadian Medical Association Journal 2002;167:363‐4. - PMC - PubMed
Saraiya 2004
    1. Saraiya M, Hall HI, Thompson T, Hartman A, Glanz K, Rimer B, et al. Skin cancer screening among U.S. adults from 1992, 1998, and 2000 National Health Interview Surveys. Preventive Medicine 2004;39(2):308‐14. [PUBMED: 15226039] - PubMed
Schünemann 2013
    1. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. Available from guidelinedevelopment.org/handbook, Updated October 2013.
Shaikh 2016
    1. Shaikh WR, Dusza SW, Weinstock MA, Oliveria SA, Geller AC, Halpern AC. Melanoma thickness and survival trends in the United States, 1989–2009. Journal of the National Cancer Institute 2016;108(1):djv294. [PUBMED: 26563354] - PMC - PubMed
Shellenberger 2016
    1. Shellenberger R, Nabhan M, Kakaraparthi S. Melanoma screening: a plan for improving early detection. Annals of Medicine 2016;48(3):142‐8. [PUBMED: 26911192] - PubMed
Stang 2016a
    1. Stang A, Garbe C, Autier P, Jöckel KH. The many unanswered questions related to the German skin cancer screening programme. European Journal of Cancer 2016;64:83‐8. [PUBMED: 27371911] - PubMed
Stang 2016b
    1. Stang A, Jöckel KH. Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig‐Holstein and Germany. Cancer 2016;122(3):432‐7. [PUBMED: 26480048] - PubMed
Sterne 2016
    1. Sterne J, Hernán MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ 2016;355:i4919. [PUBMED: 27733354] - PMC - PubMed
UKNSC 2015
    1. UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. www.screening.nhs.uk/criteria (accessed 2 June 2015).
USPSTF 2016
    1. Wernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Whitlock EP. Screening for skin cancer in adults: an updated systematic evidence review for the U.S. preventive services task force. Evidence Synthesis No. 137. AHRQ Publication No. 14‐05210‐EF‐1. Rockville, MD: Agency for Healthcare Research and Quality 2016. [PUBMED: 27583318] - PubMed
Vainio 2002
    1. Vainio H, Bianchini F. IARC handbooks of cancer prevention Vol. 7: breast cancer screening. www.iarc.fr/en/publications/pdfs‐online/prev/handbook7/Handbook7_Breast‐.... Lyon: IARC Press, (accessed 6 September 2016).
Wainstein 2015
    1. Wainstein A, Algarra SM, Bastholt L, Cinat G, Demidov L, Grob JJ, et al. Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma‐proficient countries. American Journal of Therapeutics 2015;22(1):37‐43. [PUBMED: 24914500] - PubMed
Waldmann 2012
    1. Waldmann A, Nolte S, Weinstock MA, Breitbart EW, Eisemann N, Geller AC, et al. Skin cancer screening participation and impact on melanoma incidence in Germany – an observational study on incidence trends in regions with and without population‐based screening. British Journal of Cancer 2012;106(5):970‐4. [PUBMED: 22294187] - PMC - PubMed
Welch 2005
    1. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma – population based ecological study. BMJ 2005;331(7515):481. [PUBMED: 16081427] - PMC - PubMed
Welch 2011
    1. Welch G, Schwartz L, Woloshin S. Overdiagnosed – Making People Sick in the Pursuit of Health. Boston (MA): Beacon Press, 2011.
WHO 2008
    1. Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin of the World Health Organization 2008;86(4):317‐9. [PUBMED: 18438522] - PMC - PubMed

References to other published versions of this review

Johansson 2016
    1. Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ. Screening for reducing morbidity and mortality in malignant melanoma. Cochrane Database of Systematic Reviews 2016, Issue 9. [DOI: 10.1002/14651858.CD012352] - DOI - PMC - PubMed

Publication types

MeSH terms